Imaging Technology News: First FLASH proton therapy trial completed in humans

The Cincinnati Children’s Hospital Medical Center/UC Health Proton Therapy Center recently completed enrollment in the first human trial of FLASH therapy, called FAST-01, in October.

John C. Breneman, MD, professor emeritus in the Department of Radiation Oncology in the University of Cincinnati's College of Medicine, medical director of the Cincinnati Children's Hospital Medical Center/UC Health Proton Therapy Center and a University of Cincinnati Cancer Center member, recently spoke with Imaging Technology News (ITN) about FLASH therapy and the FAST-01 trial.

 "The way that FLASH radiotherapy differs from conventional radiotherapy isn’t necessarily that it’s a different kind of radiation, it’s different because of how quickly it’s given," Breneman told ITN. "Most radiation therapy is given in treatments that may last two, three, four, five minutes. FLASH radiotherapy gives actually somewhat larger doses than what we conventionally use in day to day treatments and delivers them in just a fraction of a second, and it’s that very fast delivery of the radiation dose that seems to have the effect of being able to spare the normal tissue while still being able to kill and treat tumor tissue."

The FAST-01 trial enrolled 10 patients with bone metastases in their arms and legs, and Breneman and his team are currently conducting follow-up studies to examine potential side effects and the treatment's effectiveness to treat the cancer.

Watch the ITN interview.

Featured photo at top of Cincinnati Children’s/UC Health Proton Therapy Center's proton treatment room courtesy of Cincinnati Children's/UC Health.

Related Stories

1

OTR mural celebrates UC alumni success

April 4, 2025

The UC Alumni Association, UCAA, will mark its annual Alumni Celebration during its upcoming Alumni Week, April 7-13, with a community art project commemorating this year’s slate of alumni honorees receiving the organization’s top awards.

2

Study: Platform-predicted treatments improve outcomes for...

April 4, 2025

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an assessment of cancer stem cell sensitivity to chemotherapy can accurately decide more effective treatments and lead to increased outcomes for patients with platinum-resistant ovarian cancer.

Debug Query for this